A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine EXG-5003 against SARS-CoV-2

Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S.H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi
doi: https://doi.org/10.1101/2023.10.07.23296699

Article usage

Article usage: October 2023 to January 2025

AbstractFullPdf
Oct 2023207848
Nov 20232341634
Dec 2023120316
Jan 202469216
Feb 202453110
Mar 202450012
Apr 20243436
May 202443210
Jun 20242525
Jul 202429618
Aug 202427512
Sep 20242945
Oct 202427513
Nov 20242406
Dec 20242819
Jan 20251436
Back to top
Posted October 11, 2023.
Download PDF
Email
A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine EXG-5003 against SARS-CoV-2
Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S.H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi
medRxiv 2023.10.07.23296699; doi: https://doi.org/10.1101/2023.10.07.23296699
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area